Related Experiment Video
Updated: Feb 5, 2026

Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis
Published on: September 26, 2018
2017 ACC/AHA Blood Pressure Treatment Guideline Recommendations and Cardiovascular Risk
Lisandro D Colantonio1, John N Booth1, Adam P Bress2
1Department of Epidemiology, University of Alabama at Birmingham, Birmingham, Alabama.
Insights
The 2017 ACC/AHA guideline helps identify adults needing blood pressure medication. Implementing this guideline directs treatment to those at high cardiovascular disease risk.
Area of Science:
- Cardiology
- Hypertension Management
- Public Health
Background:
- The 2017 American College of Cardiology/American Heart Association (ACC/AHA) guideline offers updated recommendations for initiating and intensifying antihypertensive medications.
- Current clinical practice may not fully align with these updated guidelines, necessitating an evaluation of their impact on cardiovascular disease (CVD) risk.
Purpose of the Study:
- To assess the risk of cardiovascular disease (CVD) events in adults recommended for, and not recommended for, antihypertensive medication initiation or intensification based on the 2017 ACC/AHA Blood Pressure (BP) guideline.
- To evaluate the guideline's effectiveness in directing treatment to individuals with elevated CVD risk.
Main Methods:
- Analysis of data from the REasons for Geographic And Racial Differences in Stroke (REGARDS) study, including Black and White participants aged 45 years and older.
- Categorization of participants based on their need for antihypertensive medication initiation or intensification according to the 2017 ACC/AHA BP guideline, comparing CVD event rates.
- Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) were measured and averaged at baseline (2003-2007).
Main Results:
- Among those not on medication, 34.4% were recommended treatment initiation. CVD event rates were higher for those recommended initiation (22.7 per 1,000 person-years for SBP/DBP ≥140/90 mmHg) compared to those not recommended.
- For participants with SBP/DBP 130-139/80-89 mmHg not on medication, those recommended for initiation had a significantly higher CVD event rate (20.5) than those not recommended (3.4).
- Among those on medication, 62.8% were recommended intensification. Higher CVD event rates were observed in those recommended for intensification (33.6 per 1,000 person-years for SBP/DBP ≥140/90 mmHg).
Conclusions:
- The 2017 ACC/AHA guideline effectively identifies adults who would benefit from antihypertensive medication initiation and intensification.
- Adherence to the guideline directs pharmacologic treatment towards individuals with higher cardiovascular disease risk, potentially improving outcomes.
Background:
The 2017 American College of Cardiology/American Heart Association (ACC/AHA) blood pressure (BP) guideline provides updated recommendations for antihypertensive medication initiation and intensification.
Objectives:
Determine the risk for cardiovascular disease (CVD) events among adults recommended and not recommended antihypertensive medication initiation or intensification by the 2017 ACC/AHA BP guideline.
Methods:
The authors analyzed data for black and white REGARDS (REasons for Geographic And Racial Differences in Stroke) study participants (age ≥45 years). Systolic BP (SBP) and diastolic BP (DBP) were measured twice at baseline (2003 to 2007) and averaged. Participants not taking (n = 14,039) and taking (n = 15,179) antihypertensive medication were categorized according to their recommendations for antihypertensive medication initiation and intensification by the 2017 ACC/AHA guideline. Overall, 4,094 CVD events (stroke, coronary heart disease, and heart failure) occurred by December 31, 2014.
Results:
Among participants not taking antihypertensive medication, 34.4% were recommended pharmacological antihypertensive treatment initiation. The CVD event rate per 1,000 person-years among participants recommended antihypertensive medication initiation with SBP/DBP ≥140/90 mm Hg was 22.7 (95% confidence interval [CI]: 20.3 to 25.0). Among participants with SBP/DBP 130 to 139/80 to 89 mm Hg, the CVD event rate was 20.5 (95% CI: 18.5 to 22.6) and 3.4 (95% CI: 2.4 to 4.4) for those recommended and not recommended antihypertensive medication initiation, respectively. Among participants taking antihypertensive medication, 62.8% were recommended treatment intensification. The CVD event rate per 1,000 person-years among participants recommended treatment intensification was 33.6 (95% CI: 31.5 to 35.6) and 22.4 (95% CI: 20.8 to 23.9) for those with SBP/DBP ≥140/90 mm Hg and 130 to 139/80 to 89 mm Hg, respectively.
Conclusions:
Implementing the 2017 ACC/AHA guideline would direct antihypertensive medication initiation and intensification to adults with high CVD risk.
More Related Videos
Related Concept Videos
Pre-Procedural Guidelines for Assessing Blood Pressure
Blood Pressure
Blood Pressure
The average BP in an adult is typically around 120/80 mmHg (millimeters of mercury). In this measurement, the numerator (120) indicates the systolic pressure, which is the pressure in the arteries during the contraction of the heart's ventricles as blood is expelled. The denominator (80) represents the...
Measurement of Blood Pressure
Factors affecting Blood pressure
Physiological Factors:
Alterations in Blood Pressure
Hypertension (High blood pressure)
Hypertension occurs when blood pressure readings consistently exceed the normal range. It is diagnosed when systolic blood pressure (the top number, indicating pressure while the heart...

